文献速递瓣膜外科

美国70岁以下患者经导管与外科二尖瓣修复比较

Transcatheter vs Surgical Mitral Valve Repair in Patients Younger Than 70 Years in the United States.
PubMed 文献 · Ann Thorac Surg · 2026-06-26

本研究基于4个州住院数据库,纳入2013-2022年70岁以下功能性或退行性二尖瓣反流患者9542例,比较经导管二尖瓣缘对缘修复(m-TEER)与外科修复的3年结局。结果显示外科修复组3年无主要不良瓣膜相关事件(MAVRE)生存率更高(91% vs 78%),m-TEER与MAVRE风险增加相关,尤其在退行性MR患者中。

要点

  • 70岁以下MR患者中,m-TEER使用率从2016年7%增至2022年21%。
  • 外科修复组3年无MAVRE率91%,高于m-TEER组的78%。
  • 退行性MR患者中,m-TEER与MAVRE风险增加相关(aHR 1.90)。

核心结论

  • 70岁以下MR患者中,m-TEER与MAVRE风险增加相关,尤其在退行性MR患者中。

研究设计与样本

  • 回顾性队列研究,基于4个州住院数据库,纳入2013-2022年70岁以下原发性功能性或退行性MR行择期m-TEER或外科修复的患者9542例。

主要发现

  • m-TEER组1210例(12%),外科组8332例(88%);外科组更年轻(59 vs 63岁,P < .01),合并症更少,退行性病变更常见(92% vs 46%,P < .01)。
  • 2016-2022年m-TEER使用率从7%增至21%(年度百分比变化21.4%,P < .01),主要在功能性MR患者中。
  • 医院层面因素解释24%的实践变异(组内相关系数0.24;95% CI 0.14-0.34;P < .01)。
  • 3年无MAVRE率外科组高于m-TEER组(91% vs 78%;调整后风险比1.45;95% CI 1.14-1.84;P < .01)。
  • 退行性MR中,m-TEER与MAVRE风险增加相关(调整后风险比1.90;P < .01)。

临床怎么用

  • 对70岁以下MR患者,尤其退行性MR,选择m-TEER需谨慎评估,外科修复可能提供更优的中期结局。

局限性

  • 回顾性设计,可能存在选择偏倚和未测量混杂。
  • 仅纳入4个州数据库,外推性受限。
  • 缺乏解剖学细节和前瞻性随机比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mitral transcatheter edge-to-edge repair (m-TEER) use has increased, yet its outcomes compared to surgical mitral repair in younger patients are undefined. We evaluated practice trends and 3-year outcomes of m-TEER vs surgical repair for mitral regurgitation (MR) in patients aged <70 years. METHODS: Patients aged <70 years with functional or degenerative MR undergoing primary, elective m-TEER or surgical repair from 2013-2022 were identified in 4 state admissions databases. The primary outcome was freedom from major adverse valve-related events (MAVRE), a composite of death, stroke, mitral reintervention, or heart failure readmission, at 3 years compared using a multivariable Cox proportional hazard model adjusting for baseline differences. RESULTS: Among 9542 patients with MR, 1210 (12%) underwent m-TEER and 8332 (88%) underwent surgery. Patients undergoing surgery were younger (59 vs 63 years, P < .01), had fewer comorbidities, and had degenerative disease (92% vs 46%, P < .01). From 2016-2022, m-TEER use increased from 7% to 21% (annual percent change, 21.4%, P < .01), predominantly among patients with functional MR. Hospital-level factors accounted for 24% of practice variation (intraclass correlation coefficient, 0.24; 95% CI, 0.14-0.34; P < .01). Freedom from MAVRE at 3 years was higher after surgery (91% vs 78%; adjusted hazard ratio, 1.45; 95% CI, 1.14-1.84; P < .01). In degenerative MR, m-TEER was associated with increased risk of MAVRE (adjusted hazard ratio, 1.90; P < .01). CONCLUSIONS: Among patients aged <70 years with MR, m-TEER use was associated with substantial institutional variability and higher MAVRE, especially among patients with degenerative MR. These findings support the need for prospective studies to better define anatomic selection criteria and comparative effectiveness in younger patients.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Sallam A, Tam DY, Razavi A, et al. Transcatheter vs Surgical Mitral Valve Repair in Patients Younger Than 70 Years in the United States. Ann Thorac Surg. 2026. PMID: 42362134. doi:10.1016/j.athoracsur.2026.05.061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。